Oral Complications of Hematopoietic Cell Transplantation

Thomas' Hematopoietic Cell Transplantation: Stem Cell Transplantation, Fourth Edition

Volumn , Issue , 2009, Pages 1589-1607

  Schubert, Mark M ^a,b   Peterson, Douglas E ^c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b SEATTLE CANCER CARE ALLIANCE   (United States)

^c UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

Dental extractions; Dental treatment; Management of dental decay and endodontic disease; Oral complications of hematopoietic cell transplantation; Oral mucosal care; Oropharyngeal mucositis; Post HCT oral complications; Pretransplantation oral evaluation and stabilization; Prophylactic antibiotics

Indexed keywords

EID: 84878359287     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444303537.ch103     Document Type: Chapter

References (105)

1. National Cancer Institute. Oral Complications of Chemotherapy and Head/Neck Radiation. PDQ® Cancer Information Summaries: Supportive Care August 2007. Cancer Net: http://www. cancer.gov/cancertopics/pdq/supportivecare/ oralcomplications/healthprofessional (Accessed 2007).
2. Woo SB, Matin K. Off-site dental evaluation program for prospective bone marrow transplant recipients. J Am Dent Assoc 1997; 128: 189-93.
3. Peters E, Monopoli M, Woo SB, Sonis S. Assessment of the need for treatment of postendodontic asymptomatic periapical radiolucencies in bone marrow transplant recipients. Oral Surg Oral Med Oral Pathol 1993; 76: 45-8.
4. Morimoto Y, Niwa H, Imai Y, Kirita T. Dental management prior to hematopoietic stem cell transplantation. Spec Care Dentist 2004; 24: 287-92.
5. McGuire DB, Correa ME, Johnson J, Wienandts P. The role of basic oral care and good clinical practice principles in the management of oral mucositis. Support Care Cancer 2006; 14: 541-7.
6. Sonis ST, Oster G, Fuchs H et al. Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol 2001; 19: 2201-5.
7. Sonis ST, Fey EG. Oral complications of cancer therapy. Oncology (Huntington) 2002; 16: 680-6, 691-2, 695.
8. Barker GJ. Current practices in the oral management of the patient undergoing chemotherapy or bone marrow transplantation. Support Care Cancer 1999; 7: 17-20.
9. Epstein JB, Stevenson-Moore P. Periodontal disease and periodontal management in patients with cancer. Oral Oncol 2001; 37: 613-19.
10. Graber CJ, de Almeida KN, Atkinson JC et al. Dental health and viridans streptococcal bacteremia in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2001; 27: 537-42.
11. Farahani M, Eichmiller FC, McLaughlin WL. Measurement of absorbed doses near metal and dental material interfaces irradiated by X-and gamma-ray therapy beams. Phys Med Biol 1990; 35: 369-85.
12. De Rossi SS, Glick M. Dental considerations in asplenic patients. J Am Dent Assoc 1996; 127: 1359-63.
13. Majorana A, Schubert MM, Porta F, Ugazio AG, Sapelli PL. Oral complications of pediatric hematopoietic cell transplantation: diagnosis and management. Support Care Cancer 2000; 8: 353-65; comment 347-8.
14. Tunkel AR, Sepkowitz KA. Infections caused by viridans streptococci in patients with neutropenia. Clin Infect Dis 2002; 34: 1524-9.
15. Sabater Recolons Mdel M, Lopez Lopez J, Rodriguez de Rivera Campillo ME, Chimenos Kustner E, Conde Vidal JM. Buccodental health and oral mucositis. Clinical study in patients with hematological diseases. Med Oral Patol Oral Cir Bucal 2006; 11: E497-502.
16. McGuire DB. Barriers and strategies in implementation of oral care standards for cancer patients. Support Care Cancer 2003; 11: 435-41.
17. Patton LL, White BA, Field MJ. State of the evidence base for medically necessary oral health care. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001; 92: 272-5.
18. Ransier A, Epstein JB, Lunn R, Spinelli J. A combined analysis of a toothbrush, foam brush, and a chlorhexidine-soaked foam brush in maintaining oral hygiene. Cancer Nurs 1995; 18: 393-6.
19. Dodd MJ, Miaskowski C, Shiba GH et al. Risk factors for chemotherapy-induced oral mucositis: dental appliances, oral hygiene, previous oral lesions, and history of smoking. Cancer Invest 1999; 17: 278-84.
20. Dodd MJ, Larson PJ, Dibble SL et al. Randomized clinical trial of chlorhexidine versus placebo for prevention of oral mucositis in patients receiving chemotherapy. Oncol Nurs Forum 1996; 3: 21-7.
21. Dodd MJ, Dibble SL, Miaskowski C et al. Randomized clinical trial of the effectiveness of three commonly used mouthwashes to treat chemotherapy-induced mucositis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2000; 90: 39-47.
22. Rubenstein EB, Peterson DE, Schubert M et al. Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 2004; 100(9 Suppl): 2026-46.
23. Potting CM, Uitterhoeve R, Op Reimer WS, Van Achterberg T. The effectiveness of commonly used mouthwashes for the prevention of chemotherapy-induced oral mucositis: a systematic review. Eur J Cancer Care 2006; 15: 431-9.
24. McGuire DB. Mucosal injury in cancer therapy. More than mucositis and a mouthwash. Cancer Pract 2002; 10: 179-91.
25. Yeager KA, Webster J, Crain M, Kasow J, McGuire DB. Implementation of an oral care standard for leukemia and transplantation patients. Cancer Nurs 2000; 23: 40-7.
26. Bennett LL, Rosenblum RS, Perlov C, Davidson JM, Barton RM, Nanney LB. An in vivo comparison of topical agents on wound repair. Plast Reconstr Surg 2001; 108: 675-87.
27. Davies AN. The management of xerostomia: a review. Eur J Cancer Care 1997; 6: 209-14.
28. McGuire DB, Johnson J, Migliorati C. Promulgation of guidelines for mucositis management educating health care professionals and patients. Support Care Cancer 2006; 14: 548-57.
29. Vera-Llonch M, Oster G, Ford CM, Lu J, Sonis S. Oral mucositis and outcomes of autologous hematopoietic stem-cell transplantation following high-dose melphalan conditioning for multiple myeloma. J Support Oncol 2007; 5: 231-5.
30. Vera-Llonch M, Oster G, Ford CM, Lu J, Sonis S. Oral mucositis and outcomes of allogeneic hematopoietic stem-cell transplantation in patients with hematologic malignancies. Support Care Cancer 2007; 15: 491-6.
31. Stiff P. Mucositis associated with stem cell transplantation: current status and innovative approaches to management. Bone Marrow Transplant 2001; 2(Suppl): S1-11.
32. Anderson KO, Giralt SA, Mendoza TR et al. Symptom burden in patients undergoing autologous stem-cell transplantation. Bone Marrow Transplant 2007; 39: 759-66.
33. Anthony L, Bowen J, Garden A, Hewson I, Sonis S. New thoughts on the pathobiology of regimenrelated mucosal injury. Support Care Cancer 2006; 14: 516-18.
34. Sonis ST, Elting LS, Keefe D et al. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 2004; 100(Suppl 9): 1995-2025.
35. Treister N, Sonis S. Mucositis: biology and management. Curr Opin Otolaryngol Head Neck Surg 2007; 15: 123-9.
36. Schubert MM, Williams BE, Lloid ME et al. Clinical assessment scale for the rating of oral mucosal changes associated with bone marrow transplantation. Cancer 1992; 69: 2469-77.
37. Schubert MM, Jones DL. Management of oral mucositis pain. Tex Dent J 2004; 121: 507-18.
38. Epstein JB, Schubert MM. Managing pain in mucositis. Semin Oncol Nurs 2004; 20: 30-7.
39. Spielberger R, Stiff P, Bensinger W et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 2004; 351: 2590-8.
40. Stiff PJ, Emmanouilides C, Bensinger WI et al. Palifermin reduces patient-reported mouth and throat soreness and improves patient functioning in the hematopoietic stem-cell transplantation setting. J Clin Oncol 2006; 24: 5186-93.
41. Lilleby K, Garcia P, Gooley T et al. A prospective, randomized study of cryotherapy during administration of high-dose melphalan to decrease the severity and duration of oral mucositis in patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 2006; 37: 1031-5.
42. Keefe DM, Schubert MM, Elting LS et al. Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer 2007; 109: 820-31.
43. Barasch A, Elad S, Altman A, Damato K, Epstein J. Antimicrobials, mucosal coating agents, anesthetics, analgesics, and nutritional supplements for alimentary tract mucositis. Support Care Cancer 2006; 14: 528-32.
44. Blijlevens NM, Donnelly JP, de Pauw BE. Empirical therapy of febrile neutropenic patients with mucositis: challenge of risk-based therapy. Clin Microbiol Infect 2001; 7(Suppl 4): 47-52.
45. Epstein JB, Truelove EL, Oien H, Allison C, Le ND, Epstein MS. Oral topical doxepin rinse: analgesic effect in patients with oral mucosal pain due to cancer or cancer therapy. Oral Oncol 2001; 37: 632-7.
46. Epstein JB, Silverman S Jr., Paggiarino DA et al. Benzydamine HCl for prophylaxis of radiationinduced oral mucositis: results from a multicenter, randomized, double-blind, placebo-controlled clinical trial. Cancer 2001; 15: 875-85.
47. Practice guidelines for cancer pain management. A report by the American Society of Anesthesiologists Task Force on Pain Management. Cancer Pain Section. Anaesthesia 1996; 84: 1243-57.
48. Coda BA, O'Sullivan B, Donaldson G, Bohl S, Chapman CR, Shen DD. Comparative efficacy of patient-controlled administration of morphine, hydromorphone, or sufentanil for the treatment of oral mucositis pain following bone marrow transplantation. Pain 1997; 72: 333-46.
49. Schubert MM, Eduardo FP, Guthrie KA et al. A phase III randomized double-blind placebo controlled clinical trial to determine the efficacy of low energy laser therapy for the prevention of oral mucositis in patients undergoing hematopoietic cell transplantation. Support Care Cancer 2007; 15: 1145-54.
50. von Bultzingslowen I, Brennan MT, Spijkervet FK et al. Growth factors and cytokines in the prevention and treatment of oral and gastrointestinal mucositis. Support Care Cancer 2006; 14: 519-27.
51. Peterson DE, Jones JB, Petit RG. Randomized, placebo-controlled trial of Saforis for prevention and treatment of oral mucositis in breast cancer patients receiving anthracycline-based chemotherapy. Cancer 2007; 109: 322-31.
52. Epstein JB, Chow AW. Oral complications associated with immunosuppression and cancer therapies. Infect Dis Clin North Am 1999; 13: 901-23.
53. Nichols WG. Management of infectious complications in the hematopoietic stem cell transplant recipient. J Intensive Care Med 2003; 18: 295-312.
54. Baden LR, Rubin RH. Infection in the hematopoietic stem cell transplant recipient. In: Soiffer RJ, editor. Stem Cell Transplantation for Hematologic Malignancies. Totowa, NJ: Humana Press; 2004. pp. 237-58.
55. Schubert MM, Izutsu KT. Iatrogenic causes of salivary gland dysfunction. J Dent Res 1987; 66: 680-8.
56. Marr KA, Bowden RA. Fungal infections in patients undergoing blood and marrow transplantation. Transpl Infect Dis 1999; 1: 237-46.
57. Redding SW. The role of yeasts other than Candida albicans in oropharyngeal candidiasis. Curr Opin Infect Dis 2001; 14: 673-7.
58. Schubert MM, Peterson DE, Meyers JD, Hackman R, Thomas ED. Head and neck aspergillosis in patients undergoing bone marrow transplantation. Report of four cases and review of the literature. Cancer 1986; 57: 1092-6.
59. Segal BH, Almyroudis NG, Battiwalla M et al. Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjuncts. Clin Infect Dis 2007; 44: 402-9.
60. Bhatti Z, Shaukat A, Almyroudis NG, Segal BH. Review of epidemiology, diagnosis, and treatment of invasive mould infections in allogeneic hematopoietic stem cell transplant recipients. Mycopathologia 2006; 162: 1-15.
61. Sullivan KM, Dykewicz CA, Longworth DL et al. Preventing opportunistic infections after hematopoietic stem cell transplantation: the Centers for Disease Control and Prevention, Infectious Diseases Society of America, and American Society for Blood and Marrow Transplantation Practice Guidelines and beyond. Hematology Am Soc Hematol Educ Program 2001: 392-421.
62. van Kraaij MG, Verdonck LF, Rozenberg-Arska M, Dekker AW. Early infections in adults undergoing matched related and matched unrelated/ mismatched donor stem cell transplantation: a comparison of incidence. Bone Marrow Transplant 2002; 30: 303-9.
63. Arvin AM. Varicella-zoster virus: pathogenesis, immunity, and clinical management in hematopoietic cell transplant recipients. Biol Blood Marrow Transplant 2000; 6: 219-30.
64. Schubert MM, Epstein JB, Lloid ME, Cooney E. Oral infection due to cytomegalovirus in immunocompromised patients. J Oral Pathol Med 1993; 22: 268-73.
65. Lark RL, McNeil SA, VanderHyde K, Noorani Z, Uberti J, Chenoweth C. Risk factors for anaerobic bloodstream infections in bone marrow transplant recipients. Clin Infect Dis 2001; 33: 338-43.
66. Prabhu RM, Piper KE, Litzow MR, Steckelberg JM, Patel R. Emergence of quinolone resistance among viridans group streptococci isolated from the oropharynx of neutropenic peripheral blood stem cell transplant patients receiving quinolone antimicrobial prophylaxis. Eur J Clin Microbiol Infect Dis 2005; 24: 832-8.
67. Leibovici L, Paul M, Cullen M et al. Antibiotic prophylaxis in neutropenic patients: new evidence, practical decisions. Cancer 2006; 107: 1743-51.
68. Shenep JL. Viridans-group streptococcal infections in immunocompromised hosts. Int J Antimicrob Agents 2000; 14: 129-35.
69. Akintoye SO, Brennan MT, Graber CJ et al. A retrospective investigation of advanced periodontal disease as a risk factor for septicemia in hematopoietic stem cell and bone marrow transplant recipients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2002; 94: 581-8.
70. Boeckh M, Kim HW, Flowers ME, Meyers JD, Bowden RA. Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation-a randomized double-blind placebo-controlled study. Blood 2006; 107: 1800-5.
71. Ochs L, Shu XO, Miller J et al. Late infections after allogeneic bone marrow transplantation: comparison of incidence in related and unrelated donor transplant recipients. Blood 1995; 86: 3979-86.
72. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34: 909-17.
73. Dobr T, Passweg J, Weber C et al. Oral health risks associated with HLA-types of patients undergoing hematopoietic stem cell transplantation. Eur J Haematol 2007; 78: 495-9.
74. Imanguli MM, Atkinson JC, Harvey KE et al. Changes in salivary proteome following alloge neic hematopoietic stem cell transplantation. Exp Hematol 2007; 35: 184-92.
75. Oneschuk D, Hanson J, Bruera E. A survey of mouth pain and dryness in patients with advanced cancer. Support Care Cancer 2000; 8: 372-6.
76. Epstein JB, Tsang AHF, Warkentin D, Ship JA. The role of salivary function in modulating chemotherapy-induced oropharyngeal mucositis: a review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2002; 94: 39-44.
77. Nagler RM, Nagler A. Pilocarpine hydrochloride relieves xerostomia in chronic graft-versus-host disease: a sialometrical study. Bone Marrow Transplant 1999; 23: 1007-11.
78. Carpenter PA, Schubert MM, Flowers ME. Cevimeline reduced mouth dryness and increased salivary flow in patients with xerostomia complicating chronic graft-versus-host disease. Biol Blood Marrow Transplant 2006; 12: 792-4.
79. Chainani-Wu N, Gorsky M, Mayer P, Bostrom A, Epstein JB, Silverman S Jr. Assessment of the use of sialogogues in the clinical management of patients with xerostomia. Spec Care Dentist 2006; 26: 164-70.
80. Kielbassa AM, Hinkelbein W, Hellwig E, Meyer-Luckel H. Radiation-related damage to dentition. Lancet Oncol 2006; 7: 326-35.
81. Woo SB, Lee SJ, Schubert MM. Graft-vs-host disease. Crit Rev Oral Biol Med 1997; 8: 201-16.
82. Treister NS, Woo SB, O'Holleran EW, Lehmann LE, Parsons SK, Guinan EC. Oral chronic graftversus-host disease in pediatric patients after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005; 11: 721-31.
83. Imanguli MM, Pavletic SZ, Guadagnini JP, Brahim JS, Atkinson JC. Chronic graft versus host disease of oral mucosa: review of available therapies. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006; 101: 175-83.
84. Foss FM, DiVenuti GM, Chin K et al. Prospective study of extracorporeal photopheresis in steroidrefractory or steroid-resistant extensive chronic graft-versus-host disease: analysis of response and survival incorporating prognostic factors. Bone Marrow Transplant 2005; 35: 1187-93.
85. Marinone MG, Rizzom D, Ferremi P, Rossi G, Izzi T, Brusotti C. Late taste disorders in bone marrow transplantation. Clinical evaluation with taste solutions in autologous and allogeneic bone marrow recipients. Heamotologica 1991; 76: 519-22.
86. Mattsson T, Arvidson K, Heimdahl A, Ljungman P, Dahllof G, Ringden O. Alterations in taste acuity associated with allogeneic bone marrow transplantation. Oral Pathol Med 1992; 21: 33-7.
87. Iestra JA, Fibbe WE, Zwinderman AH, van Staveren WA, Kromhout D. Body weight recovery, eating difficulties and compliance with dietary advice in the first year after stem cell transplantation: a prospective study. Bone Marrow Transpl 2002; 29: 417-24.
88. Vissink A, Burlage FR, Spijkervet FK, Jansma J, Coppes RP. Prevention and treatment of the consequences of head and neck radiotherapy. Crit Rev Oral Biol Med 2003; 14: 213-25.
89. Loughran TP, Sullivan K, Morton T et al. Value of day 100 screening studies for predicting the development of chronic graft-versus-host disease after allogeneic bone marrow transplantation. Blood 1990; 76: 228-34.
90. Soares AB, Faria PR, Magna LA et al. Chronic GVHD in minor salivary glands and oral mucosa: histopathological and immunohistochemical evaluation of 25 patients. J Oral Pathol Med 2005; 34: 368-73.
91. Migliorati CA, Siegel MA, Elting LS. Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment [Review]. Lancet Oncol 2006; 7: 508-14. Erratum in: Lancet Oncol 2006; 7: 533.
92. Mavrokokki T, Cheng A, Stein B, Goss A. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 2007; 65: 415-23.
93. Advisory Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2007; 65: 369-76.
94. Migliorati CA, Casiglia J, Epstein J, Jacobsen PL, Siegel MA, Woo SB. Managing the care of patients with bisphosphonate-associated osteonecrosis: an American Academy of Oral Medicine position paper [Review]. J Am Dent Assoc 2005; 136: 1658-68. Erratum in: J Am Dent Assoc 2006; 137: 26.
95. Adornato MC, Morcos I, Rozanski J. The treatment of bisphosphonate-associated osteonecrosis of the jaws with bone resection and autologous platelet-derived growth factors. J Am Dent Assoc 2007; 138: 971-7.
96. Harper RP, Fung E. Resolution of bisphosphonate-associated osteonecrosis of the mandible: possible application for intermittent low-dose parathyroid hormone [rhPTH(1-34)]. J Oral Maxillofac Surg 2007; 65: 573-80. Erratum in: J Oral Maxillofac Surg 2007; 65: 1059.
97. Dahllof G, Jonsson A, Ulmner M, Huggare J. Orthodontic treatment in long-term survivors after pediatric bone marrow transplantation. Am J Orthod Dentofacial Orthop 2001; 120: 459-65.
98. Dahllof G. Craniofacial growth in children treated for malignant diseases. Acta Odontol Scand 1998; 56: 378-82.
99. Hölttä P, Alaluusua S, Saarinen-Pihkala S, Wolf J, Nyström M, Hovi L. Long-term adverse effects on dentition in children with poor-risk neuroblastoma treated with high-dose chemotherapy and autologous stem cell transplantation with or without total body irradiation. Bone Marrow Transplant 2002; 29: 121-7.
100. Kanda Y, Arai C, Chizuka A et al. Pyogenic granuloma of the tongue early after allogeneic bone marrow transplantation for multiple myeloma. Leuk Lymphoma 2000; 37: 445-9.
101. Gallagher G, Forrest DL. Second solid cancers after allogeneic hematopoietic stem cell transplantation. Cancer 2007;109: 84-92.
102. Curtis RE, Metayer C, Rizzo JD et al. Impact of chronic GVHD therapy on the development of squamous-cell cancers after hematopoietic stemcell transplantation: an international case-control study. Blood 2005; 105: 3802-11.
103. Leisenring W, Friedman DL, Flowers ME et al. Nonmelanoma skin and mucosal cancers after hematopoietic cell transplantation. J Clin Oncol 2006; 24: 1119-26.
104. Raut A, Huryn J, Pollack A, Zlotolow I. Unusual gingival presentation of post-transplantation lymphoproliferative disorder: a case report and review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2000; 90: 436-41.
105. Schubert MM, Correa MEP. Oral graft-versus host disease. Dent Clin N Am (in press).